A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2017
This article has no abstract
Epistemonikos ID: 6199609ebf6391cc3eb614d536074469b5637b3f
First added on: Apr 29, 2026